AngioDynamics, Inc. (NASDAQ:ANGO) Short Interest Down 18.0% in March

AngioDynamics, Inc. (NASDAQ:ANGO) was the recipient of a large decrease in short interest in March. As of March 13th, there was short interest totaling 1,784,550 shares, a decrease of 18.0% from the February 26th total of 2,176,310 shares. Based on an average trading volume of 282,420 shares, the days-to-cover ratio is presently 6.3 days. Approximately 4.6% of the company’s stock are short sold.

AngioDynamics Stock Down 0.3%

Shares of ANGO stock opened at $10.87 on Tuesday. The firm has a market cap of $448.06 million, a P/E ratio of -16.22 and a beta of 0.48. The company has a 50 day moving average of $10.81 and a 200-day moving average of $11.54. AngioDynamics has a 12-month low of $8.36 and a 12-month high of $13.99.

Institutional Trading of AngioDynamics

Several hedge funds have recently made changes to their positions in the company. Goldman Sachs Group Inc. lifted its position in shares of AngioDynamics by 9.6% during the 1st quarter. Goldman Sachs Group Inc. now owns 259,226 shares of the medical instruments supplier’s stock valued at $2,434,000 after buying an additional 22,658 shares during the last quarter. Jane Street Group LLC increased its holdings in AngioDynamics by 267.1% in the 1st quarter. Jane Street Group LLC now owns 46,803 shares of the medical instruments supplier’s stock worth $439,000 after acquiring an additional 34,054 shares during the last quarter. Legal & General Group Plc raised its stake in AngioDynamics by 279.5% in the 2nd quarter. Legal & General Group Plc now owns 12,353 shares of the medical instruments supplier’s stock valued at $123,000 after acquiring an additional 9,098 shares during the period. Rhumbline Advisers raised its stake in AngioDynamics by 4.3% in the 2nd quarter. Rhumbline Advisers now owns 61,337 shares of the medical instruments supplier’s stock valued at $608,000 after acquiring an additional 2,510 shares during the period. Finally, American Century Companies Inc. lifted its holdings in AngioDynamics by 15.8% during the second quarter. American Century Companies Inc. now owns 96,808 shares of the medical instruments supplier’s stock valued at $960,000 after purchasing an additional 13,217 shares during the last quarter. 89.43% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of research analysts recently weighed in on the stock. Weiss Ratings reissued a “sell (d-)” rating on shares of AngioDynamics in a research report on Wednesday, January 21st. Zacks Research raised shares of AngioDynamics from a “hold” rating to a “strong-buy” rating in a research report on Friday, January 9th. Finally, Wall Street Zen lowered shares of AngioDynamics from a “buy” rating to a “hold” rating in a research note on Sunday, December 21st. One investment analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating and one has issued a Sell rating to the company. According to MarketBeat.com, AngioDynamics has a consensus rating of “Moderate Buy” and an average target price of $19.33.

About AngioDynamics

AngioDynamics, Inc is a medical technology company headquartered in Latham, New York, that develops, manufactures and markets a broad range of minimally invasive medical devices. The company’s products focus on three core areas: vascular access, peripheral vascular intervention and interventional oncology. Its solutions are designed to improve procedural outcomes, reduce complications and enhance patient comfort in hospital and outpatient settings.

In the vascular access segment, AngioDynamics offers a portfolio of devices including implanted ports, peripherally inserted central catheters (PICCs), hemodialysis catheters and specialty blood management products.